IPO Year: 2017
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2025 | $8.00 | Buy | Rodman & Renshaw |
Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00
NT 10-K - Rein Therapeutics, Inc. (0001420565) (Filer)